Zomedica Corp.
Close on Oct 19, 2026
- Market cap
- $77.40M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | During market hours | $9.50M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | During market hours | $8.80M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 16, 2026 | During market hours | $10.50M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | During market hours | $8.10M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | During market hours | $7.00M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | During market hours | $6.50M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 14, 2025 | During market hours | $7.90M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 8, 2024 | Before market open | $7.00M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | During market hours | – | – | – |
Press releases
Announcements Zomedica filed with the SEC
Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity
Results of operations · EX-99.1 to Form 8-K
Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
Results of operations · EX-99.1 to Form 8-K
Zomedica Announces Third Quarter 2025 Financial Results: Revenue up 16% to $8.1 Million with 67% Gross Margins and $54 Million in Liquidity to Support Growth
Results of operations · EX-99.1 to Form 8-K
Zomedica Announces Second Quarter 2025 Financial Results: Revenue up 14% to $7 Million with 67% Gross Margins and $59 Million in Liquidity to Support Growth
Results of operations · EX-99.1 to Form 8-K
Zomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support Growth
Results of operations · EX-99.1 to Form 8-K
Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth
Results of operations · EX-99.1 to Form 8-K
Zomedica Announces First Quarter 2024 Financial Results: Revenue up 14% to $6.3 Million; 66% Gross Margin, and $91 Million in Liquidity
Results of operations · EX-99.1 to Form 8-K
Zomedica Announces Record Second Quarter 2023 Financial Results: Revenue up 43% to $6.0 Million; Strong 67% Gross Margin & $142.4 Million in Liquidity
Results of operations · EX-99.1 to Form 8-K
Zomedica Announces Record First Quarter 20 23 Financial Results: Revenue up 45% to $5.5 Million; Strong 70% Gross Margin & $147.5 Million in Liquidity
Results of operations · EX-99.1 to Form 8-K
Zomedica Exercises Option to Acquire Structured Monitoring Products
Other events · EX-99.1 to Form 8-K
Zomedica Corporation Reports 2022 Results: $18.9 Million Revenue; 72% Gross Margin & $156 Million in Liquidity
Results of operations · EX-99.1 to Form 8-K
Zomedica Reports Preliminary Results for the Fourth Quarter and Full Year 2022
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · Agreement terminated · Other events · EX-99.1 to Form 8-K
Zomedica expands relationship with Structured Medical Products and begins commercializing VetGuardian wireless monitors
Material agreement · Other events · EX-99.1 to Form 8-K
4:01 pm ET, Monday August 15, 2022
Results of operations · EX-99.1 to Form 8-K
Zomedica Acquires Assets of Leading tPEM(TM) Company Assisi Animal Health
Material agreement · Acquisition or disposition completed · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Zomedica Announces New Global Manufacturing & Distribution Center
Other events · EX-99.1 to Form 8-K
Zomedica Finalizes Acquisition of Veterinary Imaging Company Revo Squared
Acquisition or disposition completed · Unregistered share sale · Other events · EX-99.1 to Form 8-K
ZOMEDICA TO ACQUIRE ASSETS OF INNOVATIVE VETERINARY IMAGING COMPANY REVO SQUARED
Material agreement · Other events · EX-99.1 to Form 8-K
Zomedica Announces First Quarter 2022 Revenues of $3.8 Million;
Results of operations · EX-99.1 to Form 8-K
Zomedica Corporation Reports 2021 Fourth Quarter & Full Year Results
Results of operations · EX-99.1 to Form 8-K
Zomedica Announces Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
PulseVet is currently the market leader in the equine space with 1,500 systems actively in use globally. It recently launched a new handpiece, the X-Trode, which has an energy output intended for maximum efficacy while no longer requiring patient sedation.
Material agreement · Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K